Capricor Therapeutics, Inc. (NASDAQ:CAPR)
Industry: Healthcare

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. Its development stage drug candidates for cardiosphere-derived cells include CAP-1002 that is in Phase I/II clinical trial in subjects with DMD; and CAP-2003 that is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.

Current Quote*
Last: $0.902
Change: 0.000
Book: $2.808
Volume: 217

As Of: 10/18 09:47 ET
*Quotes delayed by 20min.

Graphs for CAPR


3 Month Graph


6 Month Graph


1 Year Graph